Olodaterol: a review of its use in chronic obstructive pulmonary disease

Drugs
Emma D Deeks

Abstract

Olodaterol (Striverdi(®) Respimat(®)) is an inhaled long-acting β2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD. Several well-designed phase III trials have assessed use of the drug over 6 or 48 weeks in this patient population. In these studies, once-daily olodaterol improved lung function relative to placebo over 48 weeks of treatment, with such improvements being achieved and maintained within the 24-h dosage interval, supporting its once-daily administration. In addition, combined analyses of 48-week trials indicated that olodaterol reduces rescue medication use and may also improve dyspnoea and health-related quality of life, and crossover studies showed improvements in exercise endurance after 6 weeks of treatment with the drug. Pooled analyses of crossover studies assessing 24-h bronchodilation after 6 weeks of therapy indicated that once-daily olodaterol has a 24-h bronchodilatory profile generally similar to that of once-daily tiotropium bromide and twice-daily formoterol. Olodaterol was generally well tolerated and had an acceptable cardiovascular and respiratory adverse event profile. However, further longer-term and active comparator-controlled studies ...Continue Reading

References

Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Mar 2, 2011·The Journal of Pharmacology and Experimental Therapeutics·Paola CasarosaFlorian Gantner
Aug 16, 2011·Pulmonary Pharmacology & Therapeutics·J A van NoordP J G Cornelissen
Jun 27, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Gary T FergusonPaul Sachs
Aug 13, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Neil S RoskellKarin Becker

❮ Previous
Next ❯

Citations

Aug 22, 2015·Expert Review of Clinical Pharmacology·Mario CazzolaMaria Gabriella Matera
Dec 20, 2015·Drugs·Sohita Dhillon
May 14, 2016·Expert Opinion on Investigational Drugs·Mario CazzolaJosuel Ora
May 26, 2016·Expert Review of Respiratory Medicine·Donald BanerjiNicola A Hanania
Sep 13, 2016·Expert Opinion on Drug Metabolism & Toxicology·Maria Gabriella MateraMario Cazzola
Oct 13, 2018·Expert Opinion on Pharmacotherapy·Andrea S Melani
May 24, 2019·Drugs·Hannah A Blair
Dec 14, 2016·British Journal of Clinical Pharmacology·Hyun Woo LeeChang-Hoon Lee
Feb 25, 2021·Respiratory Research·Nan YangDelbert R Dorscheid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.